Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients
Clin. transl. oncol. (Print)
; 11(7): 446-454, jul. 2009. ilus, tab
Artículo
en Inglés
| IBECS
| ID: ibc-123657
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Neutropenia is a common complication of cancer chemotherapy. Colony-stimulating factors (CSF) may be used to avoid neutropenia-associated complications. The Spanish Society of Medical Oncology (SEOM) recently constituted a working group to review the main issues concerning the use of CSF and carried out a consensus process about the use of CSF in cancer patients, held in Madrid on 26 May 2006. The group concluded the following recommendations:
prophylactic use of CSF is recommended when a rate of febrile neutropenia (FN) higher than 20% is expected without the use of CSF or when additional risk factors for neutropenia exist; therapeutic use of CSF is recommended in order to treat FN episodes but not to treat afebrile neutropenic episodes. In addition, the use of CSF is considered effective when used to mobilise stem cells before high-dose chemotherapy and when used for chemotherapy schedule optimisation in dose-dense and in dose-intense regimens (AU)
Buscar en Google
Colección:
Bases de datos nacionales
/
España
Base de datos:
IBECS
Asunto principal:
Factores Estimulantes de Colonias
/
Neoplasias
/
Neutropenia
Tipo de estudio:
Estudio de etiología
/
Guía de práctica clínica
/
Factores de riesgo
Límite:
Femenino
/
Humanos
/
Masculino
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
Clin. transl. oncol. (Print)
Año:
2009
Tipo del documento:
Artículo
Institución/País de afiliación:
Ramón y Cajal University Hospital/Spain